Table 1.
Literature review of xenogenic liver cell transplantation in immunodeficient mouse models.
| Reference | Year | Recipient animal | Induced liver deficiency model | Transplanted cells | Duration of the study | Engraftment efficiency (%) and outcome | Precised mouse type |
|---|---|---|---|---|---|---|---|
| Vidal et al. [18] | 2008 | Nude mice | Jo2 250 μg/kg weekly | Sprague-Dawley rat hepatocyte | 3 weeks | 4.2% | Balb/c Nude mice |
| Rhim et al. [19] | 1995 | uPA-Nude mice | uPA | Sprague-Dawley rat hepatocyte | 8 weeks | Reach 100% | uPA mice crossed with Swiss athymic nude (nu/nu) mice |
| Mahieu-Caputo et al. [20] | 2004 | Nude mice | PHx 50% | Human fetal hepatoblast (11–13 WG) | 6 weeks | 0.05 to 5% (increased if liver biopsies were repeated) |
Athymic mice |
| Nowak et al. [21] | 2005 | Nude mice | GalN IP 0.7 g/kg 36 h prior to transplantation | CD117+/CD34+/Lin-human fetal liver cell (6–10 WG) | 4 weeks | 4-5% (differentiation into mature hepatocytes and cholangiocytes) |
C57 Black/nude mice |
| Joshi et al. [22] | 2012 | Nude mice | Retrorsine 70 mg/kg and PHx 30% | Human fetal hepatocyte/liver mesenchymal cell | 4 weeks | 12% (MSC enhanced liver repopulation) |
C57BL/6 nude mice |
| Woo et al. [23] | 2012 | Nude mice | CCl4 10 μL/20 g | Hepatocyte-like cells derived from human embryonic stem cell (iPS) | 5 weeks | 20–23% (hepatoprotective effect obtained by delivering trophic factors) |
Balb/c nude mice |
| Banas et al. [24] | 2009 | Nude mice | CCl4 10 μL/20 g | Adipose-derived stem cells derived hepatocyte-like cells | One day |
? (Protect against liver damage) |
Balb/c nude mice |
| Jiang et al. [25] | 2010 | SCID beige mice | Jo2 0.2 mg/kg weekly | Human HepaRG cell line | 10 weeks | 15–20% | SCID beige mice |
| Su et al. [26] | 2011 | Fah−/−Nod/SCID mice and FK506 treatment | Fah | Human hepatocyte | 6 weeks | 0.6–18% (chimerism successful in 8/14 mice) |
Fah−/−Nod/SCID mice |
| Azuma et al. [27] | 2007 | Fah−/−/Rag2−/−/Il2Rg−/− mice | uPA adenovirus transfert | Human hepatocyte | 8 to 12 weeks | >1% for 17/73 mice >30% for 7/17 |
Fah/Rag2/Il2rg triple mutants |
| Dandri et al. [28] | 2001 | uPA/Rag2−/− mice | uPA | Human hepatocyte | 4 weeks | 2–10% (But no engraftment in 3/10 mice) |
uPA/Rag2−/− mice |
| Haridass et al. [29] | 2009 | uPA+/−/rag2−/−/γc−/− | uPA | Mouse and human hepatocyte and fetal liver cell | 3 months | Mouse hepatocyte 46% Mouse fetal cells 5–12% Human hepatocyte 10% Human fetal cells 2.7% |
uPA+/−/rag2−/−/γc−/− mice |
| Hasegawa et al. [30] | 2011 | TK-NOG mice | Ganciclovir | Human hepatocyte | Up to 8 months | 43% | Nonobese diabetic/SCID/IL2Rγ −/− mice |
| Douglas et al. [31] | 2010 | vTK-SCID/uPA | Hepatic failure induced by Gancyclovir (for hepatocyte bearing HSVtk plasmide) | Human hepatocyte | 8 weeks | No survival of mice | SCID/uPA mice |
WG: weeks of gestation, PHx: partial hepatectomy, GalN: Galactosamine, uPA: uroplasminogen activator, Fah: fumarylacetoacetate hydrolase, MSC: mesenchymal stem cells, and CCl4: carbon tetrachloride.